

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number
12-10094-01

Docket or Reference number
030-01517

Amendment No. 35

St. Francis Hospital
Department of Radioisotopes
12935 S. Gregory Street
Blue Island, IL 60406

In accordance with letter dated May 8, 1985, License Number 12-10094-01 is amended as follows:

Conditions 12. and 17. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Luke Pascale, M.D.

Groups I, II, III, IV and V
Xenon-133
In vitro studies

Richard We'llyn, M.D.

Groups I, II, III, IV and V
Xenon-133
In vitro studies

Shankar Sanwalani, M.D.

Groups I, II, III, IV, V and VI
Xenon-133
In vitro studies

S. J. Shirazi, M.D.

Group VI

John W. Laude, M.D.

Groups I, II and III
Xenon-133
In vitro studies
Iodine-131 as iodide for treatment
of hyperthyroidism, cardiac
dysfunction, and thyroid carcinoma

G. M. Tolentino, M.D.

Groups VI

Jayant Ginde, M.D.

Group VI

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated September 20, 1983; letters dated January 12 1984, July 23, 1984, and May 8, 1985; and ALARA Program dated August 13, 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Date May 22, 1985

Original Signed
By Patricai J. Whiston
Materials Licensing Section, Region III

8506100836 850522
REG3 LIC30
12-10094-01 PDR

COPY 211

ML 308

3-22-85